We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
成纤维细胞生长因子21与妊娠期代谢性疾病的研究进展.
- Authors
李晶晶; 孙晓彤; 柳婷婷; 李振英; 张一凡; 苏妍
- Abstract
Gestational metabolic diseases (GMD) are the most common cause of maternal and neonatal outcomes, but the mechanism remains unclear. Fibroblast growth factor 21 (FGF21) is a polypeptide hormone synthesized by a variety of organs. Its mechanism of action is complex. It regulates a series of metabolic processes in vitro and in vivo, and mainly participates in metabolic activities such as glucose, lipid, energy regulation and hepato -intestinal circulation of bile acid by means of endocrine. It also plays a key role in cell proliferation and differentiation, neuronal development, angiogenesis and wound healing. Therefore, FGF21 release disorders, signal dysregulation, and abnormal function are closely associated with GMD such as gestational diabetes mellitus, gestational hypertension disease, and intrahepatic cholestasis of pregnancy. This article reviews the latest research progress on the mechanism of FGF21 in GMD, so as to identify GMD and its hidden disease as early and accurate as possible, achieve the purpose of early diagnosis and intervention, and ultimately improve the prognosis of mothers and infants.
- Publication
Journal of International Obstetrics & Gynecology, 2023, Vol 50, Issue 4, p400
- ISSN
1674-1870
- Publication type
Article
- DOI
10.12280/gjfckx.20230156